India, Nov. 9 -- Charles River Laboratories International, Inc. (CRL) announced Monday that it has entered into definitive agreements to acquire Hong Kong-based Frontage Holdings Corp.'s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, subject to customary closing adjustments.
In addition to the initial purchase price, the transaction includes additional payments of up to $75 million, contingent on future performance of the acquired businesses.
The planned acquisition will expand Charles River's capabilities in the high-growth clinical bioanalysis sector and enhance its ability to support clients from early-stage research through clinical development.
The transaction complements Charles River...